Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.

Dairy intake has no effect on daytime ambulatory BP

11 Jan 2020
Cheese and other dairy products may actually be good to prevent type 2 diabetes and lower the risk of heart diseases, according to several studies.

Compared with a dairy-free diet, consumption of dairy products with low or regular fat demonstrates no overall effect on daytime ambulatory blood pressure (BP), suggests a recent study.

“Other cardiometabolic risk factors may be differently modified according to the fat content of the dairy product,” the investigators noted.

Fifty-five healthy men and women with high-normal daytime BP participated in this crossover controlled feeding study. Participants were randomized to sequences of three 6-week isoenergetic diets, each comprising no dairy (control diet), 3 daily servings of 1-percent fat milk and 1 daily serving of 31-percent fat cheddar cheese naturally enriched in γ-aminobutyric acid.

The investigators matched the total fats, carbohydrates and proteins across all three diets. The additional 2 percent of energy from saturated fatty acids in the cheese diet was replaced by n–6 polyunsaturated fatty acids in the other diets.

No difference was seen in the postdiet ambulatory systolic (p=0.34) and diastolic (p=0.45) BP among the three groups. The cheese diet resulted in an elevation in serum low-density lipoprotein (LDL) cholesterol concentrations compared with the control (5.8 percent; p=0.006) and milk (7.0 percent; p=0.0008) diets, and an increase in LDL particle size compared with the milk diet (p=0.02).

Compared with the control diet, the milk diet reduced high-density lipoprotein cholesterol concentrations (–4.1 percent; p=0.009), while the milk and cheese diets increased triglycerides (9.9 percent; p=0.01 and 10.5 percent; p=0.007, respectively).

No significant difference was seen between all diets for C-reactive protein concentrations and markers of glucose/insulin homeostasis.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.